Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives

Background: The clinical evaluation of HER2CLIMB trial showed a 21. 9-month median overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for patients with human epidermal growth factor receptor 2 (HER2) –overexpressing metastatic breast cancer. From the payer&#...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiuji, Liao, Weiting, Zhang, Mengxi, Huang, Jiaxing, Zhang, Pengfei, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417356/
https://www.ncbi.nlm.nih.gov/pubmed/32850425
http://dx.doi.org/10.3389/fonc.2020.01336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417356/
https://www.ncbi.nlm.nih.gov/pubmed/32850425
http://dx.doi.org/10.3389/fonc.2020.01336

Ejemplares similares